Tagged with R

USA Once centred on building awareness, the Alliance for Regenerative Medicine has grown into the world’s foremost advocate for the cell and gene therapy sector, bringing together more than 400 members across biotech, pharma, academia, and patient organisations. In this conversation, CEO Timothy Hunt discusses how the field is moving from…

USA Global pharma is rushing to relocate manufacturing to the US. To reduce dependence on foreign manufacturing sources – most notably from its main economic adversary, China – the Trump administration is putting pressure on pharma to situate production on US soil. This pressure is predominantly taking the form of economic…

Denmark Drawn from Healthcare & Life Sciences Review Denmark 2025, this selection captures the major forces now reshaping one of Europe’s most dynamic life science hubs. From Denmark’s bid to double the sector’s economic weight by 2030, to its sweeping “Health Closer to You” reform, biotech surge, clinical-trials strategy, and evolving…

Global First published in the September/October 2025 edition of ISPOR’s Value & Outcomes Spotlight, David Thompson (Rubidoux Research), Christopher Blanchette (Clinical, Medical and Regulatory Affairs), and Stephanie Earnshaw (Access Strategy Consulting) explore how health economics and outcomes research (HEOR) careers are being reshaped by a fast-changing industry. The authors examine why…

Global First published in the November 2025 issue of DIA’s Global Forum, this article by Victoria Gamermanusa (RWD Insights) tackles one of rare disease research’s toughest dilemmas: how to run credible efficacy trials when patient numbers make traditional statistics unworkable. She charts how AI, Bayesian methods, transfer learning, and synthetic data…

UK First published in the November 2025 edition of DIA’s Global Forum, this piece by Jane Morrin O’Rourke, Naho Yamazaki, Becky Purvis (HRA) and Mandy Budwal-Jagait, Jason Wakelin-Smith and Kingyin Lee (MHRA) dives into one of the UK’s most urgent research challenges: how to make clinical trials genuinely inclusive. The authors…

USA Duane Barnes, President of Sobi North America, outlines how the company has rapidly expanded its presence in the region to become a key player in rare diseases, growing its US business more than twenty-fold over the past decade. He discusses Sobi’s strong focus on haematology and immunology, the company’s upcoming…

China China is rapidly maturing into a global hub for innovation, offering speed, scale, and cost advantages in clinical trials that few markets can match. Andy Liu, Managing Director China for Novotech– a full-service clinical research organisation (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies…

LatAm Constanza Losada, VP & General Manager for Latin America at BMS, leads one of the company’s fastest-growing regions, driving access to innovation, regional collaboration, and talent mobility. With major investments in clinical research, digital health, and cell therapy, she positions Latin America as a hub for growth and global impact…

Mexico Adriana Eguia Alaniz is President of Tijuana EDC, leading efforts to diversify and strengthen the region’s economy. Under her leadership, Tijuana has strengthened its role as a major medical device export hub, with 55,000 workers, $3B in exports, and 40+ global companies. Her priorities include cross-border speed-to-market, supply chain resilience,…

Brazil Rogerio Frabetti, General Manager of Biogen Brazil discusses the organisation’s strategic transformation as it expands beyond its neuroscience heritage into immunology whilst maintaining leadership in rare diseases. He articulates Brazil’s elevation to a top-tier global market, outlines ambitious growth trajectories in Alzheimer’s disease and lupus, and addresses the complexities of…

LatAm Gianclaudio Broggi is CEO and chairman of Megalabs, one of Latin America’s largest biopharma organisations with operations spanning more than 20 countries and a workforce exceeding 9,000 employees. With over two decades at the company, he has been instrumental in its transformation from a 120 million USD enterprise into a…